336 related articles for article (PubMed ID: 33785297)
1. The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR).
Bergin K; Wellard C; Moore E; McQuilten Z; Blacklock H; Harrison SJ; Ho PJ; King T; Quach H; Mollee P; Walker P; Wood E; Spencer A;
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e510-e520. PubMed ID: 33785297
[TBL] [Abstract][Full Text] [Related]
2. Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR).
Bergin K; Wellard C; Augustson B; Cooke R; Blacklock H; Harrison SJ; Ho J; King T; Quach H; Mollee P; Walker P; Moore E; McQuilten Z; Wood E; Spencer A;
Bone Marrow Transplant; 2021 Oct; 56(10):2533-2543. PubMed ID: 34011965
[TBL] [Abstract][Full Text] [Related]
3. Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry.
Lim SL; Wellard C; Moore E; Harrison SJ; Hang Q; Ho J; Rajagopal R; Spencer A
Intern Med J; 2024 May; 54(5):773-778. PubMed ID: 38149340
[TBL] [Abstract][Full Text] [Related]
4. Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry.
Bergin K; Moore E; McQuilten Z; Wood E; Augustson B; Blacklock H; Ho J; Horvath N; King T; McNeil J; Mollee P; Quach H; Reid CM; Rosengarten B; Walker P; Spencer A
BMC Med Res Methodol; 2016 Nov; 16(1):151. PubMed ID: 27829380
[TBL] [Abstract][Full Text] [Related]
5. Māori and Pacific Peoples With Multiple Myeloma in New Zealand are Younger and Have Inferior Survival Compared to Other Ethnicities: A Study From the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
Moore EM; Blacklock H; Wellard C; Spearing R; Merriman L; Poplar S; George A; Baker B; Chan H; McQuilten ZK; Wood EM; Spencer A;
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e762-e769. PubMed ID: 35501256
[TBL] [Abstract][Full Text] [Related]
6. Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.
Radocha J; Maisnar V; Pour L; Špička I; Minařík J; Szeligová L; Pavlíček P; Jungová A; Krejčí M; Pika T; Straub J; Brožová L; Stejskal L; Heindorfer A; Jindra P; Kessler P; Mikula P; Sýkora M; Wróbel M; Jarkovský J; Hájek R
Cancer Med; 2018 Aug; 7(8):4132-4145. PubMed ID: 29931775
[TBL] [Abstract][Full Text] [Related]
7. The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR).
Aoki N; Chen PY; Chen W; Chng WJ; Gan GG; Goh YT; Hou J; Huang J; Kim K; Lee JJ; Lu J; McQuilten ZK; Min CK; Moore E; Oliver L; Waters NA; Wellard C; Wood EM; Yeh SP; Spencer A;
BMC Med Res Methodol; 2024 May; 24(1):102. PubMed ID: 38698331
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of the revised international staging system for newly diagnosed multiple myeloma patients].
Lu J; Du J; Fu WJ; He HY; Li L; Li R; Zhou LL; Jiang H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):475-479. PubMed ID: 28655089
[No Abstract] [Full Text] [Related]
9. [Application of the Second Revision of the International Staging System (R2-ISS) in the prognostic assessment of newly diagnosed multiple myeloma].
Yan J; Zhou DM; Shao XY; Xu Y; Chen B
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):170-177. PubMed ID: 38604794
[No Abstract] [Full Text] [Related]
10. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
11. Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
Ho PJ; Moore EM; McQuilten ZK; Wellard C; Bergin K; Augustson B; Blacklock H; Harrison SJ; Horvath N; King T; Mollee P; Quach H; Reid C; Rosengarten B; Walker P; Wood EM; Spencer A
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e415-e424. PubMed ID: 31208889
[TBL] [Abstract][Full Text] [Related]
12. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
13. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
14. Revised International Staging System Applied to Real World Multiple Myeloma Patients.
Jimenez-Zepeda VH; Duggan P; Neri P; Rashid-Kolvear F; Tay J; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):511-518. PubMed ID: 27425179
[TBL] [Abstract][Full Text] [Related]
15. Natural history of multiple myeloma with de novo del(17p).
Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Dispenzieri A; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Blood Cancer J; 2019 Mar; 9(3):32. PubMed ID: 30846679
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805).
Kim K; Kim JS; Yoon SS; Yoon DH; Eom HS; Lee JJ; Yim HW; Park M; Lee H; Min CK;
Int J Hematol; 2022 Jul; 116(1):110-121. PubMed ID: 35543899
[TBL] [Abstract][Full Text] [Related]
17. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
D'Agostino M; Cairns DA; Lahuerta JJ; Wester R; Bertsch U; Waage A; Zamagni E; Mateos MV; Dall'Olio D; van de Donk NWCJ; Jackson G; Rocchi S; Salwender H; Bladé Creixenti J; van der Holt B; Castellani G; Bonello F; Capra A; Mai EK; Dürig J; Gay F; Zweegman S; Cavo M; Kaiser MF; Goldschmidt H; Hernández Rivas JM; Larocca A; Cook G; San-Miguel JF; Boccadoro M; Sonneveld P
J Clin Oncol; 2022 Oct; 40(29):3406-3418. PubMed ID: 35605179
[TBL] [Abstract][Full Text] [Related]
18. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
[No Abstract] [Full Text] [Related]
19. [Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma].
Zhou HX; Jian Y; Du J; Liu JR; Zhang ZY; Geng CY; Yang GZ; Wang GR; Fu WJ; Li J; Chen WM; Gao W
Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):81-88. PubMed ID: 38186122
[No Abstract] [Full Text] [Related]
20. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma.
Wadhera RK; Kyle RA; Larson DR; Dispenzieri A; Kumar S; Lazarus HM; Rajkumar SV
Blood; 2011 Sep; 118(11):2985-7. PubMed ID: 21765020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
